BLUE stock icon

bluebird bio
BLUE

$0.97
0.54%
 

About: bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Employees: 323

0
Funds holding %
of 6,656 funds
0
Analysts bullish %
of 9 analysts
0
News positive %
of 153 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

60% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 35

59% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 39

35.27% more ownership

Funds ownership: 83.91% [Q3] → 119.18% (+35.27%) [Q4]

13% more funds holding

Funds holding: 165 [Q3] → 186 (+21) [Q4]

13% less call options, than puts

Call options by funds: $2.27M | Put options by funds: $2.63M

34% less capital invested

Capital invested by funds: $273M [Q3] → $180M (-$92.9M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$1.02
6%
upside
Avg. target
$5.52
471%
upside
High target
$12
1,142%
upside

9 analyst ratings

positive
33%
neutral
56%
negative
11%
RBC Capital
Luca Issi
728%upside
$8
Sector Perform
Reiterated
27 Mar 2024
Wells Fargo
Yanan Zhu
210%upside
$3
Equal-Weight
Maintained
27 Mar 2024
Wedbush
David Nierengarten
74%upside
$1.68
Neutral
Maintained
19 Mar 2024
HSBC
Morten Herholdt
6%upside
$1.02
Reduce
Maintained
5 Mar 2024
B of A Securities
Jason Gerberry
417%upside
$5
Buy
Maintained
21 Dec 2023

Financial journalist opinion

Based on 153 articles about BLUE published over the past 30 days